Abcam gains after securing all approvals for Danaher sale, set to close Dec. 6
Abcam gains after securing all approvals for Danaher sale, set to close Dec. 6
Abcam ticks higher amid report of China approval for sale to Danaher
Shareholders of Abcam approve proposed acquisition by Danaher
Abcam holder Starboard Value said to sell stake - report
Abcam holders should vote for sale to Danaher, proxy adviser ISS says
Abcam received multiple bids in sales process, contacted over 30 parties
5.12BUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
-
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
June
IPO date
-
Updated At
-
PE Ratio
2,225.00
PEG Ratio
-
Book Value
3.14
Dividend Share
-
Dividend Yield
-
Earnings Share
0.01
Wall Street Target Price
-
EPS Estimate Current Year
-
EPS Estimate Next Year
-
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
379,700,000
Gross Profit TTM
270,500,000
EBITDA
106,000,000
Profit Margin
0.66%
Return On Assets TTM
4.36%
Return On Equity TTM
0.35%
Revenue Per Share TTM
1.658
Qtly Revenue Growth YOY
9.70%
Diluted Eps TTM
0.01
Qtly Earnings Growth YOY
188.00%
Trailing PE
2225.00
Forward PE
32
Price Sales TTM
13.4866
Price Book MRQ
5.6658
Enterprise Value Revenue
11
Enterprise Value EBITDA
67
283.34
11.60%80.47
0.68%32.60
0.46%697.42
0.00%155.00
0.00%76.98
-2.30%97.06
-1.75%503.20
-1.34%190.32
-1.26%658.48
-0.59%